Results 31 to 40 of about 213,311 (303)
Trends and patterns of neurotology drug prescriptions on a nationwide insurance database
Laryngoscope Investigative Otolaryngology, 2021 Objective To examine neurotologists' 2013 to 2016 Medicare Part‐D data and evaluate commonly prescribed medications, longitudinal changes in prescribing patterns, presumed associated pathologies, and cost distribution across United States.
Khodayar Goshtasbi +8 more
doaj +1 more source
Coverage of New Drugs in Medicare Part D
The Milbank Quarterly, 2022 Policy Points Only a small minority of new drugs in “nonprotected” classes are widely covered by Part D plans nationwide in the year after US Food and Drug Administration (FDA) approval. Part D plans frequently apply utilization management restrictions such as prior authorizations to newly approved drugs in both protected and nonprotected classes ...
NACI, HUSEYIN +5 more
openaire +2 more sources
Effects of star ratings bonus payments on disparities in medication utilization issues
Exploratory Research in Clinical and Social Pharmacy, 2023 Background: Previous literature suggested that the consequences of inappropriate medication use may be borne disproportionately by racial/ethnic minorities.
Chi Chun Steve Tsang +4 more
doaj +1 more source
Suit the action to the word, the word to the action: Hypothetical choices and real decisions in Medicare Part D [PDF]
, 2012 In recent years, consumer choice has become an important element of public policy. One reason is that consumers differ in their tastes and needs, which they can express most easily through their own choices.
Heiss, Florian +3 more
core +2 more sources
Effects of Part D Star Ratings on racial and ethnic disparities in health care costs
Exploratory Research in Clinical and Social Pharmacy, 2023 Background: Racial/ethnic minorities are less likely than non-Hispanic White (White) patients to be included in the Medicare Part D Star Ratings measure assessment due to the restrictive inclusion criteria for the measures. Objective: This paper examined
Chi Chun Steve Tsang +3 more
doaj +1 more source
A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Uremic toxins are a growing area of research in nephrology, with significant implications in the progression and treatment of chronic kidney disease (CKD) and the management of end‐stage kidney disease (ESKD). This bibliometric analysis aims to evaluate the global research trends, key contributors, and the impact of publications in ...
Yuh‐Shan Ho +7 more
wiley +1 more source
Changes in the Cost of Medicare Prescription Drug Plans, 2007-2008 [PDF]
, 2007 This issue brief analyzes the increase in Medicare Part D premiums over the past year and finds, on average, a 24.5 percent rise. It goes on to look at Medicare Part D statistics on a state-by-state basis to show trends that are not readily apparent ...
Dean Baker, Joshua Lanier
core
Aging and Cancer, EarlyView.ABSTRACT As global populations age, cancer is increasingly becoming a leading cause of morbidity and mortality among older adults, particularly in low‐ and middle‐income countries (LMICs). Despite accounting for the majority of new cancer cases and deaths, older individuals remain underrepresented in cancer research, clinical guidelines, and health ...
Ibrahim Bidemi Abdullateef +2 more
wiley +1 more source
Eligibility and Take-up of the Medicare Part D Low-Income Subsidy
Inquiry: The Journal of Health Care Organization, Provision, and Financing, 2012 There is concern about poor take-up of the Medicare Part D Low-Income Subsidy (LIS), but uncertainty in published estimates. The Medicare Current Beneficiary Survey (MCBS), which contains Medicare LIS enrollment records and extensive survey data on ...
J. Samantha Shoemaker +5 more
doaj +1 more source
Sex Differences in Medication Discontinuation in Axial Spondyloarthritis
Arthritis Care &Research, EarlyView.Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall +9 more
wiley +1 more source